LAVA Therapeutics NV (LVTX) Actualités

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq:...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

​​UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT OF FOREIGN ISSUERPURSUANT TO...

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a...